B+
Bull case
30%
Probability
Target price
$760.00
Analysis reference price unavailable
Analysis 2026-10-26 · RankAlpha Sentiment Codex
TMO
Thermo Fisher ScientificANYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The primary release confirms 6% organic growth and 120 basis points of adjusted-margin expansion [#SEC-8K-2026-10-21]. The call transcript records higher full-year revenue, EPS and cash-flow guidance.
Posture
Constructive
Lead driver
Value
What changed
7 setup hits (3d) with net bullish as of 2026-10-27.
What can break
Clario integration, strategic reinvestment and unfavorable mix could offset productivity and constrain margin gains, as described in the earnings-call transcript.
Momentum
92
Value
60
Sentiment
60
Setup hits (3d)
7 · Net Bullish
AI TargetsBase $710.00 · Bull $760.00 · Bear $600.00Analysis 2026-10-26; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-27 • Vendor: Data Vendor v1
Scores
As of 2026-10-27 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-26 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-27
Investment thesis
As of 2026-10-27
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-27. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Bullish
Target $761.72
Why
Momentum92 · Δ7d +2.1
Value60 · Δ7d -0.1
Sentiment60 · Δ7d +10.5
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.
Confirming evidence
- • 7 setup hits (3d) with net bullish as of 2026-10-27.
- • Value remains the lead driver in the composite, 7D delta -0.1.
Contradictions & invalidation
- • Clario integration, strategic reinvestment and unfavorable mix could offset productivity and constrain margin gains, as described in the earnings-call transcript.
- • Product and collaboration announcements have no disclosed revenue contribution in the cited Q3 release [#SEC-8K-2026-10-21].
- • The call transcript attributes part of the quarter’s EPS benefit to roughly $60 million of net tariff-refund recovery and retains 4% Q4 organic-growth guidance, below Q3’s 6%; this weakens extrapolation of the Q3 beat.
Catalyst clock
2026-11-06
Q3 earnings beat meets a fading share-price reaction
Lead driver: Value · See fundamentals
Momentum
92
8% active weight
Current posture
7d trendImproving
Δ7d
+2.1
Δ21d
+2.5
Value
60
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.9
Sentiment
60
45% active weight
Current posture
7d trendImproving
Δ7d
+10.5
Δ21d
+3.5
Why this grade
Composite grade A. Momentum 91.9 / Value 60.2 / Sentiment 59.8
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-26. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$710.00
Analysis reference price unavailable
Analysis 2026-10-26 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$600.00
Analysis reference price unavailable
Analysis 2026-10-26 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-27
Fundamentals (TTM)
As of 2026-10-27
Market Cap
$256.24B
Beta
0.93
Shares Out
369.75M
P/E (TTM)
35.3
P/S (TTM)
5.25
P/FCF (TTM)
41.85
Rev YoY
+10.5%
EPS YoY
+9.4%
Gross Margin
+40.2%
Op Margin
+19.1%
Net Debt
$30.75B
Current Ratio
1.55
As of 2026-10-27 • Updated nightlySource: Internal modelMethods & Data